GW&K Investment Management LLC Trims Holdings in Merck & Co., Inc. (NYSE:MRK)

GW&K Investment Management LLC trimmed its position in Merck & Co., Inc. (NYSE:MRK) by 6.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 460,168 shares of the company’s stock after selling 32,632 shares during the quarter. GW&K Investment Management LLC’s holdings in Merck & Co., Inc. were worth $38,737,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Titan Capital Management LLC CA acquired a new stake in Merck & Co., Inc. during the second quarter worth about $25,000. LFA Lugano Financial Advisors SA grew its holdings in Merck & Co., Inc. by 250.0% during the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares during the period. JJJ Advisors Inc. acquired a new stake in Merck & Co., Inc. during the second quarter worth about $27,000. Cumberland Partners Ltd acquired a new stake in Merck & Co., Inc. during the second quarter worth about $40,000. Finally, Fusion Family Wealth LLC grew its holdings in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares during the period. Hedge funds and other institutional investors own 74.95% of the company’s stock.

MRK traded up $0.71 during trading on Friday, hitting $83.59. The company’s stock had a trading volume of 6,053,527 shares, compared to its average volume of 10,105,755. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $87.35. The business’s fifty day simple moving average is $84.01 and its 200 day simple moving average is $82.77. The firm has a market capitalization of $212.31 billion, a price-to-earnings ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The company had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. During the same period last year, the company earned $1.19 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 14.9% compared to the same quarter last year. As a group, equities research analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Several analysts recently commented on the company. ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Bank of America assumed coverage on Merck & Co., Inc. in a report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 target price on the stock. Svb Leerink assumed coverage on Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 target price on the stock. JPMorgan Chase & Co. set a $96.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. Finally, Mizuho raised their target price on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Co., Inc. currently has an average rating of “Buy” and an average target price of $95.13.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: What causes a stock to be most active?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.